|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-9-4
|
|
pubmed:abstractText |
Hemoglobin increases have been associated with quality of life (QOL) improvements in anemic cancer patients treated with epoetin alfa, but intervention generally has been reserved for symptomatic anemia or hemoglobin < 10 g/dL. Relationships among hemoglobin, functional status, and patient reported QOL have not been well characterized.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10763
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
888-95
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
|
|
pubmed:affiliation |
Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase IV
|
